St. Jude Medical Gains Market Share, Increases Outlook On Strong ICD Sales
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical took another two to three points of global implantable cardioverter defibrillator market share in the first half of the year, on the back of 40 ICD and pacemaker product launches in the past two years, the company said July 16
You may also be interested in...
St. Jude manufacturing expansion
St. Jude Medical is set to begin manufacturing cardiac rhythm management devices at its new Arecibo, Puerto Rico, plant, following FDA approval of the facility July 31, firm announces Aug. 20. Production of pacemakers and cardiac leads will come first, with implantable cardioverter defibrillators to be added late this year, St. Jude says. St. Jude is poised to capture 24% of the worldwide ICD market for 2008, Wachovia analyst Larry Biegelsen predicted in mid-July (1"The Gray Sheet" July 21, 2008, p. 14)
St. Jude manufacturing expansion
St. Jude Medical is set to begin manufacturing cardiac rhythm management devices at its new Arecibo, Puerto Rico, plant, following FDA approval of the facility July 31, firm announces Aug. 20. Production of pacemakers and cardiac leads will come first, with implantable cardioverter defibrillators to be added late this year, St. Jude says. St. Jude is poised to capture 24% of the worldwide ICD market for 2008, Wachovia analyst Larry Biegelsen predicted in mid-July (1"The Gray Sheet" July 21, 2008, p. 14)
Medtronic ICD Sales Better Than Expected, But Some Share Goes To St. Jude
Medtronic's sales of implantable cardioverter defibrillators beat analyst expectations in the most recent fiscal quarter despite lingering fall-out from the firm's October Fidelis ICD lead recall